Compare Amazon.com Inc (AMZN) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amazon.com Inc vs Citius Pharmaceuticals Inc — how do they compare? Amazon.com Inc trades at $268.3 (market cap $2.94T), while Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M). The key difference: Amazon.com Inc is far larger — about 146926.5× Citius Pharmaceuticals Inc's market cap, and Amazon.com Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMZN | CTXR | |
|---|---|---|
Market Cap | $2.94T | $20.01M |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $284.02 | $1.82 |
52-Week Low | $198.79 | $0.48 |
Enterprise Value | $3.04T | $16.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $267.84, down 3.69% over 24 hours, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals, including a 17.44% net income margin and robust revenue growth to $716.92 billion in 2025. Recent news highlights CEO Andy Jassy's optimistic outlook on AWS and AI chip expansion, fueling investor confidence.
Outlook remains positive with a consensus price target of $333.86, indicating 25% upside potential. Risks include intense competition in e-commerce and cloud services, alongside high capital expenditures. Wall Street sentiment is overwhelmingly bullish, with 89% of analysts rating it a buy, though volatility from macroeconomic factors warrants caution.
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
